Preferred Partner Network (PPN) members will become Centers of Excellence for the IRO® platform combining best-in-class technology with industry-leading development and manufacturing capabilities.
PHILADELPHIA and LONDON, UK, March 18, 2025 – Oribiotech Ltd. (Ori), a leader in cell and gene therapy (CGT) manufacturing technology, today announced the launch of its Preferred Partner Network (PPN), bringing together top academic medical centers (AMCs) and contract development and manufacturing organizations (CDMOs) to deliver best-in-class solutions to accelerate development and commercialization of cell and gene therapies. The founding members of the Ori Preferred Partner Network in the U.S. include Charles River Laboratories, CTMC (a joint venture between MD Anderson Cancer Center and Resilience), ElevateBio, Kincell and other currently undisclosed partners.
Read the full press release here: Ori Biotech’s Preferred Partner Network